|
[Background] androgen can promote gender differentiation to maintain male sexuality and reproductive function, also has an important role in regulating substance metabolism. Its blood glucose, blood lipids, inflammatory factors, adipocytokines and body components have an important impact. A number of large prospective clinical study confirmed that low testosterone levels in adult males, increased risk of diabetes. The same time, reduce the level of androgens, and male obesity, dyslipidemia and other metabolic syndrome risk factors are closely linked. Androgen levels may cause the pronouns one of the important reasons for the metabolic syndrome. Recently, abroad on male hormones and metabolic syndrome, the correlation between the number of research articles has increased rapidly, while domestic research is still rare. Adolescent males hypogonadism insulin sensitivity and substance metabolic abnormalities aspects of study abroad rare, the domestic yet to see the reports. [Objective] 1. Adolescent male hypogonadism and normal adolescent male, insulin sensitivity is different. Hypogonadism adolescent males, nine months of testosterone replacement therapy can improve a patient's insulin sensitivity. 3 short-term androgen replacement therapy, adolescent male hypogonadism secondary sexual characteristics, height, weight, abdominal circumference, grip strength, body fat, blood lipids and hsCRP impact. [Method] study is divided into two parts: Part I: A case-control study; sick group of 21 cases a clear diagnosis of hypogonadism adolescent males, the control group of 11 cases of age and body mass index-matched healthy men. Compare two groups of staff blood level of total testosterone (TT), fasting glucose, fasting insulin and HOMA-IR index [HOMA-IR = FBG (mmol / L) × FINS (uIU / ml) / 22.5] whether there are differences. Part II: 18 cases of hypogonadism patients line androgen replacement therapy 9 months (program: the first three months of testosterone undecanoate capsules 40mg tid, after 6 months of testosterone undecanoate 250mg im qm) comparing treatment before and after the patients height, weight, abdominal circumference, grip strength, body fat, blood TT, fasting glucose and insulin levels, HOMA-IR index, blood lipids and hS-CRP changes. [Results] The first part: 1. Hypogonadism group, age 20.9 ± 5.7 years, TT level was 0.9 ± 0.6nmol / L, control group, age 22.3 ± 2.4 years, TT level 18.8 ± 3.2nmol of / L. Fasting glucose levels, 3h OGTT glucose curve area between the two groups, no statistically significant differences: 3h OGTT insulin area under the curve, the existence of significant differences between the two groups. Hypogonadism group the OGTT diagnostic 3/21 patients with impaired glucose tolerance (IGT). IGT or DM in the control group. Hypogonadism group fasting insulin levels were significantly higher than that of the control group, the two groups were 12.3 ± 5.5 and 5.9 ± 3.3uIU/mL, P = 0.18: the hypogonadism group of HOMA-IR index was significantly higher than that of the control group the two groups were 2.68 ± 1.7 and 1.2 ± 0.75, P = 0.021; Part II: patients with hypogonadism, androgen replacement therapy (9 months), blood testosterone levels significantly increased, Second sexual characteristics significant development, height, weight, grip strength, hemoglobin were significantly increased (P <0.05). 2 fasting insulin levels after treatment decreased significantly before and after treatment were 16.0 ± 9.8 and 12.1 ± 7.4uIU/mL, P = 0.03; HOMA-IR index also decreased significantly, were 3.7 ± 2.4 and 2.7 ± 1.7, P = 0.045; fasting glucose levels decreased, but there was no significant difference. Androgen replacement therapy, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein (UDL-c) and triglyceride (TG) has a downward trend, but no statistically significant difference (P> 0.05). No significant changes in patients with body fat content, before and after treatment were 23.69 ± 3.7% and 23.85 ± 5.6%, P = 0.84 after treatment significantly decreased hs-CRP levels before and after treatment were 1.49 ± 1.18mg / L and 0.70 ± 0.56mg / L, P = 0.025. [Conclusion] and compared to their peers healthy young male patients with hypogonadism decreased insulin sensitivity. Androgen replacement therapy can improve the patient's insulin sensitivity. Short-term (9 months) androgen replacement therapy, the hypogonadism young men can height, weight, grip strength, hemoglobin increased significantly, so the obvious development of secondary sexual characteristics, so that the total cholesterol, LDL-c, HDL-c decreased hs-CRP decreased significantly. However, before and after the treatment, the patient's body fat content without significant changes of.
|